Management/Board of Directors

Raoul Concepcion U.S. Urology Partners

Raoul S. Concepcion, MD, FACS

Chief Science Officer

Raoul S. Concepcion is the newly appointed Chief Science Officer of U.S. Urology Partners. Dr. Concepcion has decades of experience as a pioneer and clinician at the forefront of the urology industry, including serving as a founding member and former President of LUGPA, the premier nonprofit association and advocate for independent urology practices.

A native of central Ohio, Dr. Concepcion has been a Clinical Assistant Professor in the Department of Urology, Vanderbilt University School of Medicine. He was a General Surgery and Urology Resident from 1984 to 1989 and served as Chief Urology Resident from 1989 to 1990. Additionally, he was a research fellow in the Light Laboratories at Vanderbilt. More recently, he has completed The City of Hope Intensive Course on Cancer Risk Assessment for hereditary cancer and genomic testing. He has been in practice since 1990, with his major clinical interest being Urologic Oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction, as well as the role of genomics and genetic testing in GU tumors. He is Board Certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeons and the Nashville Surgical Society.

From a research perspective, Dr. Concepcion has been actively in involved in basic science and clinical research since his days at Vanderbilt. Dr. Concepcion has been either the principal investigator (PI) or Co-PI on many clinical trials since the 1990s. The focus as of recent has been in advanced prostate cancer, as well as biomarker development.  He co-founded CUSP, a Urology specific clinical trials management company that specializes in site and patient accrual for the pharmaceutical and biolab industries. From an industry perspective, Dr. Concepcion serves as an advisor, consultant or speaker for many companies involved in the diagnosis and management of prostate cancer. He is developing a precision medicine comprehensive prostate cancer program for U.S. Urology Partners and affiliated groups, centered on genomic testing, pathway development, data aggregation and clinical trial work.